2020 · BULLETIN DU CANCER

Systemic treatment of locally advanced or metastatic penile cancer

Gassian, Noemie, Frontczak, Alexandre, El Kaddissi, Antoine, Calcagno, Fabien, Almotlak, Hamadi, Barkatz, Johann, Mouillet, Guillaume, Maurina, Tristan, Stein, Ulrich, Thierry Nguyen Tan Hon, Murez, Thibaut, Thiery-Vuillemin, Antoine

Journal: BULLETIN DU CANCER
Année: 2020
Volume: 107
Numéro: 5, S
Pages: S17-S23
Mois: JUN

Abstract

Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.